Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | ACP3 | P15309 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MAN2A1 | Q16706 | 3/20 | 0.47 |
| ▸ | MAN1B1 | Q9UKM7 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MAN2B1 | O00754 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1848481 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| SCHEMBL4853220 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| SCHEMBL6472595 | 0.89 | ADRB2 (0.50) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| SCHEMBL6514671 | 0.88 | ATM (0.66) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| Hydrochloric Acid SCHEMBL6473470 | 0.88 | ADRB2 (0.52) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| SCHEMBL323957 | 0.88 | ADRB2 (0.56) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| SCHEMBL2602792 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| SCHEMBL22445577 | 0.84 | TDP1 (0.58) | ADRB2L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL12493466 | 0.84 | TDP1 (0.58) | ADRB2L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL323594 | 0.82 | BCHE (0.55) | ATMEPHX2MAPTMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007672-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12491185-B2 | Inhibitors of mPTP | NRG THERAPEUTICS LTD (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4652162-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250177397-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| WO-2024153946-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2024-07-25 | — | — | WO | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-8163944-B2 | Allylic oxidations catalyzed by dirhodium catalysts under aqueous conditions | UNIVERSITY OF MARYLAND COLLEGE PARK (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2420487-A1 | NOVEL METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120022271-A1 | NOVEL METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090093638-A1 | Allylic Oxidations Catalyzed by Dirhodium Catalysts under Aqueous Conditions | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093638-A1 | Allylic Oxidations Catalyzed by Dirhodium Catalysts under Aqueous Conditions | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491185-B2 | Inhibitors of mPTP | PARK7, PINK1, SNCA | SMN1; SMN2 1036/4885ADRB2 424/4885ACP3 1604/4885 |
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | SMN1; SMN2 445/4885ADRB2 2412/4885ACP3 3118/4885 |
| US-20120022271-A1 | NOVEL METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUND | PPOX, CBR3, ALDH18A1 | SMN1; SMN2 4498/4885ADRB2 2312/4885ACP3 1467/4885 |
| US-20250177397-A1 | INHIBITORS OF MPTP | PARK7, PINK1, SNCA | SMN1; SMN2 1036/4885ADRB2 424/4885ACP3 1604/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | SMN1; SMN2 445/4885ADRB2 2412/4885ACP3 3118/4885 |
| US-20260007672-A1 | INHIBITORS OF MPTP | PARK7, SNCA, CYC1 | SMN1; SMN2 995/4885ADRB2 54/4885ACP3 4298/4885 |
| US-20090093638-A1 | Allylic Oxidations Catalyzed by Dirhodium Catalysts under Aqueous Conditions | CYP11B2, DHCR7, ZDHHC7 | SMN1; SMN2 4353/4885ADRB2 1731/4885ACP3 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.